Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0272
EDITORIAL
|
Developing new targeted drugs for resectable gastric cancer.
|
Dimitrios Schizas, MD, PhD.
|
Affiliation:Dimitrios Schizas, (DS), 1st Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Tel:+302651005571
E-mail: schizasad@gmail.com |
Abstract
Standardized D2 gastrectomy with adjuvant chemotherapy for resected gastric cancer has improved survival, but recurrence and mortality rates remain high. The recent advent of genome analysis with IWC Replica Watches next-generation sequencing (NGS) opens new therapeutic avenues for overcoming the clinical unmet needs.
(Citation: Gastric & Breast Cancer 2018; 13(1): 1-7)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
